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Background: Daratumumab (D), a human CD38 IgGκmonoclonal antibody, induces
deep and durable responses with a favorable safety profile in RRMM pts. We report a
pre-specified interim analysis of the first randomised, controlled study of D (CASTOR;
NCT02136134).
Methods: Pts with ≥1 prior line of therapy were randomised (1:1) to 8 cycles q3w of
bortezomib (V)/dexamethasone (d) (V: 1.3 mg/m2 sc on Days 1, 4, 8, 11; d: 20 mg po
on Days 1, 2, 4, 5, 8, 9, 11, 12) ± D (16 mg/kg iv qw in Cycles 1-3, Day 1 of Cycles 4-8,
then q4w until progression). Primary endpoint was PFS.
Results: 498 pts (DVd, 251; Vd, 247) were randomised. Baseline demographics and
disease characteristics were well balanced. Pts received a median of 2 prior lines of
therapy (range 1-10). 76% received prior IMiD; 66% received prior V; 48% received
prior PI and IMiD; 33% were IMiD-refractory; 32% were refractory to last line of prior
therapy. With a median follow-up of 7.4 months, D significantly improved PFS (61%
reduction in risk of progression), ORR, rates of ≥VGPR, rates of ≥CR, and delayed
time to next therapy (Table). Median OS was NR in both groups. Most common
(>25%) AEs (DVd/Vd) were thrombocytopenia (59%/44%), peripheral sensory
neuropathy (47%/ 38%), diarrhea (32%/22%) and anemia (26%/31%). Most common
grade 3/4 AEs (>10%) were thrombocytopenia (45%/33%), anaemia (14%/16%),
neutropenia (13%/4%). 7%/9% of pts discontinued due to a TEAE. D-associated
infusion-related reactions (45% of pts) mostly occurred during the first infusion; most
were grade 1/2 (grade 3/4, 9%/0%). Additional subgroup analyses will be presented.
Table: 906O DVd Vd
Continued
. Continued
DVd Vd
PFS
Median, mo NR 7.2
HR (95% CI) 0.39 (0.28-0.53)
P <0.0001
ORR, % 83 63
P <0.0001
≥VGPR, % 59 29
P <0.0001
≥CR, % 19 9
P 0.0012
Time to next therapy
Median, mo NR 9.8
HR (95% CI) 0.30 (0.20-0.45)
P <0.0001
Conclusions: D in combination with Vd significantly improved PFS and ORR and
delayed time to next therapy vs Vd alone. DVd doubled both VGPR and sCR/CR rates
vs Vd alone. Safety of DVd is consistent with the known safety profile of D and Vd.
The addition of D to Vd should be considered a new standard of care for RRMM pts
currently receiving Vd alone.
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